BMT-06: Phase II Study of Intensity Modulated Total Marrow Irradiation (IM-TMI) in Addition to Fludarabine/Cyclophosphamide and Post-Transplant Cyclophosphamide Conditioning for Partially HLA Mismatched Allogeneic Transplantation in Patients With Acute Leukemia and Myelodysplastic Syndrome (MDS)
This study is testing a special, targeted type of radiation called Intensity Modulated Total Marrow Irradiation alongside standard treatments. Researchers want to see if this approach kills more cancer cells in the bone marrow and lowers the chances of acute leukemia or myelodysplastic syndrome returning after a transplant.
You may be able to join if you are between 18 and 75 years old, have acute leukemia or myelodysplastic syndrome, and have a compatible family donor or an acceptable unrelated donor for your stem cell transplant. You must also meet certain heart, lung, and liver health requirements.
Before receiving blood-forming stem cells from your donor, you will get standard medications along with the special targeted radiation therapy to prepare your body for the transplant. The medical team will closely monitor your health and recovery throughout the process.
This study is currently recruiting participants and takes place in Chicago, Illinois, United States.
- 1Tests a targeted radiation method to better fight leukemia and myelodysplastic syndrome
- 2Open to adults aged 18 to 75 with a suitable stem cell donor
- 3Currently recruiting patients in Chicago, Illinois
Related links
Outside pages about this study, checked by our team
This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.